Identifying the molecular mechanisms responsible for the resistance of gliomas to anticancer treatments is an issue of great therapeutic interest. D 9 -Tetrahydrocannabinol (THC), the major active ingredient of marijuana, and other cannabinoids inhibit tumor growth in animal models of cancer, including glioma, an effect that relies, at least in part, on the stimulation of autophagymediated apoptosis in tumor cells. Here, by analyzing the gene expression profile of a large series of human glioma cells with different sensitivity to cannabinoid action, we have identified a subset of genes specifically associated to THC resistance. One of these genes, namely that encoding the growth factor midkine (Mdk), is directly involved in the resistance of glioma cells to cannabinoid treatment. We also show that Mdk mediates its protective effect via the anaplastic lymphoma kinase (ALK) receptor and that Mdk signaling through ALK interferes with cannabinoid-induced autophagic cell death. Furthermore, in vivo Mdk silencing or ALK pharmacological inhibition sensitizes cannabinod-resistant tumors to THC antitumoral action. Altogether, our findings identify Mdk as a pivotal factor involved in the resistance of glioma cells to THC pro-autophagic and antitumoral action, and suggest that selective targeting of the Mdk/ALK axis could help to improve the efficacy of antitumoral therapies for gliomas.
Glioblastoma multiforme (GBM), or grade IV astrocytoma, is the most frequent class of malignant primary brain tumor and one of the most aggressive forms of cancer. As a consequence, median survival after diagnosis is usually just 12-15 months. 1, 2 This dramatic behavior is mainly due to the high invasiveness and proliferation rate of GBM. In addition, GBM exhibits a high resistance to standard chemotherapy and radiotherapy. Current strategies for the treatment of GBM are only palliative, and include surgical resection (which is frequently incomplete because of the proximity of the tumor to vital brain structures) and focal radiotherapy. A large number of chemotherapeutic agents (e.g. alkylating agents such as temozolomide and nitrosureas such as carmustine) have also been tested, but they display limited efficacy. 1 It is therefore essential to develop new therapeutic strategies for the management of GBM. Recently, much effort has been made to understand GBM in terms of its underlying genetic lesions. 3, 4 This approach, together with the use of gene expression profile studies, may help to precisely characterize these tumors, thus allowing the identification of factors for resistance to different anti-glioma therapies and the development of specific targeted therapies. 5 The hemp plant Cannabis sativa produces B70 unique compounds known as cannabinoids, of which D
9
-tetrahydrocannabinol (THC) is the best characterized owing to its high potency and abundance. 6 THC exerts a wide variety of biological effects by mimicking endogenous substances -the endocannabinoids anandamide and 2-arachidonoylglycerol -that bind to and activate specific cannabinoid receptors. 6 So far, two G protein-coupled cannabinoid-specific receptors have been cloned and characterized from mammalian tissues: CB 1 , abundantly expressed in the brain and at many peripheral sites, and CB 2 expressed in the immune system and also present in microglia, some neuron sub-populations and glioma cells. 7 One of the most active areas of research in the cannabinoid field is the study of the potential application of cannabinoids as antitumoral agents. 8 Thus, cannabinoid administration has been shown to curb the growth of several models of tumor xenografts in rats and mice, 8 including gliomas. [9] [10] [11] On the basis of this preclinical evidence, a pilot clinical study has been conducted to investigate the effect of THC on recurrent GBM. 12 The mechanism of cannabinoid antitumoral action relies on the ability of these agents to inhibit tumor angiogenesis, inhibit cell cycle progression and stimulate cancer cell death. 8, 13 We have recently found that cannabinoids activate an endoplasmic reticulum (ER) stress-related signaling route that leads to the upregulation of the transcriptional co-activator p8 and its target the pseudo-kinase tribbles homolog 3 (TRB3). 9, 14 The stimulation of this pathway promotes autophagy via TRB3-mediated inhibition of the Akt/mammalian target of rapamycin complex 1 (mTORC1) axis and is indispensable for the pro-apoptotic and antitumoral action of THC. 15 The present work was undertaken to identify the molecular factors responsible for the resistance of glioma cells to cannabinoid antitumoral activity. By using DNA microarrays we have identified a gene expression profile characteristic of THC-resistant glioma cells. We also show that one of the genes upregulated in cannabinoid-resistant glioma cells, the growth factor Mdk, acting through the anaplastic lymphoma kinase (ALK) receptor, has a pivotal role in enhancing the resistance to cannabinoid-evoked autophagy-mediated cell death. Our results support that targeting of the Mdk/ALK axis could help to improve the efficacy of antitumoral therapies for gliomas.
Results
Identification of the gene expression profile characteristic of THC-resistant glioma cells. To gain insight into the molecular features associated with the resistance of glioma cells to cannabinoid action, we initially characterized 10 human glioma cell lines on the basis of their different sensitivity to THC-induced cell death (Figure 1a) . Thus, cell lines were classified as cannabinoid sensitive (IC 50 for THC lower than 2.5 mM) and cannabinoid resistant (IC 50 for THC higher than 2.5 mM). To note, we did not find any correlation between the sensitivity of these cell lines to THC and to other two chemotherapeutic agents (carmustine and temozolomide) frequently used in glioma treatment (Supplementary Figures 1A, B and C) , which indicates that the resistance to THC action is determined by specific mechanisms distinct from those promoting resistance to other drugs. In addition, differences in the levels of CB 1 or CB 2 receptors of glioma cells did not correlate with a higher or lower sensitivity to THC-induced cell death (Figure 1b) , and pharmacological blockade of CB 1 receptors with the selective antagonist SR141716 or CB 2 receptors with the selective antagonist SR144528 abrogated THC-induced death in both sensitive and resistant cell lines (Figure 1c and Supplementary Figure 1D ). This supports that mechanisms other than changes in the expression or the functionality of CB receptors are responsible for the differences in THC sensitivity of glioma cells. Analysis of some of the genes most frequently altered in gliomas (p16, PTEN, p53 and EGFR) did not reveal association between the presence of mutations, amplifications or deletions on those genes and sensitivity to cannabinoid treatment (data not shown). Therefore, in order to identify the molecular factors that determine the different sensitivity of glioma cells to THC, we analyzed by DNA microarrays the gene expression profile of the 10 glioma cell lines. After selection of those genes whose expression was significantly changed (FDRo0.2) at least 2.5-fold in more than three sensitive or resistant cell lines Figure 2B and  Supplementary Tables 3 and 5) , we selected 20 genes as potential candidates to predict the resistance of glioma cells to cannabinoid action. Next, we analyzed the expression of these genes in primary cultures of glioma cells obtained from tumor samples of GBM patients (in which we confirmed that THC promoted cell death via stimulation of cannabinoid receptors; Supplementary Figure 3D) . Data revealed that 8 of the 20 initially selected genes were differentially upregulated in the cultures that were more resistant to THC-induced cell death (Figures 2c and d, Supplementary Figure 3A and Supplementary Table 4 ). These observations support that this set of genes is strongly associated with a higher resistance of glioma cells to THC-induced death.
The growth factor Mdk confers resistance to THC. One of the genes whose upregulation was more strongly associated with the resistance of glioma cells to cannabinoid treatment was the growth factor Mdk; Mdk mRNA levels were 30-to 80-fold higher in the resistant than in the sensitive cell lines (Figures 2b and d and Supplementary Figures 4A and  C) . Mdk is a member of the pleiotrophin (PTN)/Mdk family and was originally described as a developmentally regulated, heparin-bound, neurotrophic factor. 16, 17 Mdk has been proposed to modulate the proliferation and migration of various types of cancer cells and is often overexpressed in malignant tumors. 18, 19 Of interest, analysis of samples from 201 glioma patients (including 115 GBMs) revealed that Mdk expression is associated to a lower overall survival of glioma, high-grade glioma and GBM patients (Figure 3a Table 6 ).
We found that the levels of Mdk are increased in the supernatants of the cannabinoid-resistant glioma cell lines (Figure 3b ). We therefore investigated whether this growth factor participates in the mechanism of resistance to cannabinoid antitumoral action of gliomas. In agreement with this possibility, Mdk silencing sensitized two cannabinoid-resistant cell lines (Figure 3c and Supplementary Figure 6A ) as well as a primary culture of glioma cells (Figure 3d ) to THC-induced cell death. Moreover, incubation with conditioned medium derived from the cannabinoid resistant cell line T98 (which was enriched in Mdk) (Figure 3e ) or with exogenous Mdk (Figure 3f ) rendered the cannabinoid-sensitive line U87 resistant to THC treatment, an effect that was abrogated by Mdk neutralization with an antiMdk antibody (Figure 3e and Supplementary Figure 6B ). These observations strongly support that Mdk is a factor for resistance to THC-induced glioma cell death.
Of note, the cannabinoid-resistant pancreatic cancer cell line Panc1 exhibited much higher levels of Mdk than the cannabinoid-sensitive pancreatic cancer cell line MiaPaca2 (Supplementary Figures 7A and B) . Furthermore, Mdk knockdown rendered Panc1 cells sensitive to THC, suggesting that a similar mechanism of resistance to cannabinoid-induced cell death also operates in pancreatic cancer cells (Supplementary Figure 7C) .
Mdk promotes resistance to THC through stimulation of the ALK receptor. The mechanism by which Mdk mediates its different biological actions has not been completely clarified 16 and may involve the stimulation of several receptors, including ALK, protein-tyrosine phosphatase, receptor-type, zeta-1 (RPTPZ), and low-density lipoprotein receptor-related protein 1 (LRP1). 16 It has been proposed that the pro-survival and pro-angiogenic effect of Mdk on tumor cells relies on the stimulation of the ALK receptor. 20 ALK was expressed in all the cell lines and primary cultures Mdk inhibits the activation of the cannabinoid-evoked autophagy-mediated cell death pathway. We have recently found that THC stimulates autophagy in glioma cells and that the activation of this cellular process is required for the pro-apoptotic and antitumoral action of cannabinoids. 15 We therefore asked whether the mechanism by which Mdk promotes resistance to THC-induced cell death could be based on the modulation of the signaling route that regulates Figure 12) . Moreover, incubation of U87 cells with T98 cell-conditioned medium or with exogenous Mdk decreased THC-induced autophagy (Figure 5d ) and apoptosis ( Figure 5e ) in response to THC. These data strongly support that the Mdk/ALK axis modulates THC-induced autophagy.
Induction of autophagy in many cellular settings relies on the inhibition of the mammalian mTORC1, which in turn regulates the activity of several autophagy proteins involved in the early triggering of this cellular process. 21 Accordingly, THC stimulates an ER stress-related pathway that leads to the upregulation of the transcription factor p8 and its downstream target TRB3. This latter protein triggers the inhibition of the Akt/mTORC1 axis, thus leading to the stimulation of autophagy-mediated cell death. 15 On the other hand, ALK stimulation has been shown to activate the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. 20 Therefore, we investigated whether the resistance to THCinduced autophagy exerted by Mdk relied on the modulation of p8/TRB3 expression and/or on the activation of the Akt/ mTORC1 axis. In line with this idea, THC-triggered p8 and TRB3 induction in T98 and HG2 cells was strongly enhanced by Mdk or ALK knockdown (Figure 6a and Supplementary Figure  11C) . Furthermore, a decrease in the phosphorylation of Akt and S6 (a well-established readout of mTORC1 activity) was observed upon THC treatment of Mdk-or ALK-silenced T98 and HG2 cells (Figure 6b and Supplementary Figure 11D) . On the other hand, incubation of U87 cells with T98 cell-conditioned medium or with exogenous Mdk decreased THC-induced p8 and TRB3 upregulation (Figure 6c ) and attenuated THC inhibition of Akt and S6 phosphorylation (Figure 6d ). Taken together, these observations strongly support that Mdk (via ALK) modulates p8/TRB3 expression as well as the activity of the Akt/mTORC1 axis to prevent the stimulation of autophagymediated cell death by cannabinoids.
In vivo silencing of Mdk sensitizes cannabinoidresistant tumors to THC anticancer action. To analyze the in vivo relevance of our findings, we generated tumor xenografts by subcutaneous injection of T98 or U87 cells in nude mice. In agreement with our in vitro data, T98 cellderived tumors exhibited higher levels of Mdk and were more resistant to THC treatment than the ones generated with U87 cells (Supplementary Figures 13A, B and C) . To investigate whether Mdk is responsible for the resistance to THC antitumoral action we analyzed the effect of THC on the growth of T98 tumor xenografts in which Mdk expression had been knocked-down (Figure 7b and Supplementary Figure 13D ). As shown in Figure 7a and in Supplementary Figure 13E , in vivo silencing of Mdk rendered established T98 cell-derived tumors sensitive to THC treatment, although it did not affect tumor growth by itself. Subsequent analysis of tumor samples revealed that Mdk silencing correlated with a decrease in ALK phosphorylation (Figure 7c) . Moreover, THC treatment increased TRB3 expression (Figure 7d , upper panels), decreased S6 phosphorylation (Figure 7d , middle panels), enhanced autophagy (as determined by LC3 immunostaining (Figure 7d, lower panels) ) and induced apoptosis (as determined by active caspase-3 immunostaining (Figure 7e) ) only in those tumors in which Mdk expression had been knocked-down. Finally, we investigated the participation of ALK on the resistance of T98 tumors to THC antitumoral action. To this aim we analyzed the effect of the coadministration of THC and NVP-TAE-684 on the growth of T98 tumor xenografts. Similar to what we observed on Mdk silencing, administration of NVP-TAE-684 decreased ALK phosphorylation and sensitized established T98 cellderived tumors to THC treatment, but did not affect tumor growth by itself (Figures 8a and b) . Furthermore, THC treatment increased TRB3 expression (Figure 8c , upper panels), decreased S6 phosphorylation (Figure 8c , middle panels), enhanced autophagy (Figure 8c , lower panels) and induced apoptosis (Figure 8d ) only in those tumors in which ALK had been inhibited. Altogether, these results strongly support that the Mdk/ALK axis promotes resistance to THC antitumoral action in vivo by modulating the activation of the autophagy mediated-cell death pathway.
Discussion
GBM is one of the most aggressive forms of cancer, in part, owing to its poor response to standard radiotherapy and chemotherapy. Consequently, it is currently believed that the design of successful therapeutic strategies to manage these tumors should be based on their detailed molecular characterization, which would allow the development of more specific and personalized treatments. [3] [4] [5] In line with this line of reasoning, in this study we aimed to identify the molecular features associated with the resistance of gliomas to cannabinoid antitumoral action. Our data show that the level of expression of CB 1 or CB 2 receptors does not determine the sensitivity of glioma cells to THC-induced cell death. This is in line with previous observations by our group and others showing that activation of either CB 1 9,10,15 or CB 2 14,22,23 receptors leads to tumor cell death, thus suggesting that additional factors are responsible for the differences in cannabinoid sensitivity. Detailed analysis of the gene expression profile of a series of cell lines and primary cultures of human glioma cells has led us to find a panel of genes whose upregulation is associated with differences in sensitivity to THC-induced cell death. On the one hand, this information will allow setting the basis for predicting which specific GBM patients could be more susceptible of being treated with cannabinoids. On the other hand, the genes that are selectively upregulated in the cannabinoid-resistant glioma cells become potential candidates to have a direct role in the resistance to THC. Several observations strongly support that at least one of these genes, the growth factor Mdk, is directly responsible for the resistance to cannabinoid antitumoral action: (i) Mdk levels are much higher in cannabinoid-resistant than in cannabinoid-sensitive glioma cells, (ii) incubation with Mdk-enriched conditioned medium or with exogenous Mdk renders cannabinoid-sensitive glioma cells resistant to THCinduced cell death, (iii) knockdown of Mdk sensitizes cannabinoid-resistant glioma cells to THC killing action, and (iv) in vivo silencing of Mdk renders cannabinoid-resistant tumors sensitive to THC antitumoral action. Mdk is frequently overexpressed in malignant tumors and has been proposed to act as a protective factor against cell death, 19,24 although the precise mechanism by which Mdk mediates this effect has not been clarified. At least four receptors, namely ALK, N-syndecan, RPTPz and LRP1, have been proposed to mediate the biological activities of Mdk. 16 Although controversial data have been published with respect to the notion that Mdk acts as a ligand of the ALK receptor, 20, [25] [26] [27] data presented here demonstrate that the mechanism by which Mdk promotes resistance to THCinduced cell death relies on ALK. Thus, we observed that ALK silencing abolishes the protective effect exerted by an MDKenriched conditioned medium or by the addition of exogenous Mdk on glioma cells. Likewise, genetic or pharmacological inhibition of ALK enhances THC-induced cell death in cannabinoid-resistant cells. Moreover, treatment with the ALK-selective inhibitor NVP-TAE684 sensitizes cannabinoid resistant tumors to THC anticancer action.
Of interest, alterations in ALK have been implicated in cancer progression. In particular, ALK fusion proteins associated to chromosome translocations are present in most anaplastic large cell lymphomas, a subset of non-Hodgkin lymphomas, as well as in several solid tumors including nonsmall cell lung cancer. 28 In addition, gain-of-function mutations, mostly harbored in the kinase domain of ALK, have been associated to both familiar and sporadic cases of neuroblastoma. [29] [30] [31] [32] By contrast, to the best of our knowledge no studies have been published reporting the presence of these alterations in glioma patients. Moreover, we did not find any mutation in the ALK kinase domain of the glioma cells used in this study (Supplementary Table 7 ). Taken together, these observations support that increased ligand production rather than mutations or amplifications of the ALK gene are responsible for the stimulation of this receptor in glioma cells. To note, no correlation between PTN (a Mdk-related protein with high homology with Mdk) expression and resistance to THC-induced cell death was found in this study (Supplementary Figure 4B ), which further supports that the mechanism of resistance to THC-induced cell death in glioma cells specifically relies on the increased expression of Mdk. Our data are therefore in agreement -at least in part -with the proposal that ALK is a dependence receptor 27, 33 that has an antiapoptotic role only when is activated/stimulated by its ligand. Of potential therapeutic relevance, we found that increased expression of Mdk is associated with decreased survival of GBM patients, which further supports that this ligand may have an important role in promoting resistance to cancer therapies.
We also show that Mdk, through stimulation of ALK, promotes resistance to THC-induced cell death by interfering with the induction of autophagy by cannabinoids. The mechanism by which Mdk inhibits THC-induced autophagy relies on the modulation of the Akt/mTORC1 axis. ALK, as other tyrosine kinase receptors, is coupled to PI3K/Akt. 34 Accordingly, we found that Mdk stimulates Akt in human glioma cell lines. However, our data also show that, in the absence of THC, silencing of ALK or Mdk decreases Akt phosphorylation in cannabinoid-resistant glioma cells without leading to either inhibition of the mTORC1 complex or autophagy. These observations suggest that additional signals -as those triggered by THC -are necessary for the stimulation of autophagymediated cell death in glioma cells. Interestingly, we also found that p8 and TRB3 only become upregulated in response to THC treatment in cannabinoid-resistant cells when Mdk or ALK have been silenced. Taken together, these results support that Mdk and ALK promote resistance to THC-induced autophagy via stimulation of Akt and modulation of the expression of the proautophagic genes p8 and TRB3.
In summary, we have found that increased expression of the growth factor Mdk and subsequent activation of ALK are critically involved in the promotion of glioma resistance to cannabinoid antitumoral action. Furthermore, experiments with tumor xenografts demonstrate that inhibition of the Mdk/ ALK axis sensitizes cannabinoid-resistant tumors to THC treatment, which correlates with an enhanced activation of autophagy and apoptosis in these tumors. Antitumoral therapies based on the selective targeting of tyrosine kinase receptors are currently being used for the management of different types of cancer. 35, 36 Moreover, resistance to different chemoterapeutic agents frequently relies on a gain of function of the signaling routes activated by tyrosine kinase receptors. [36] [37] [38] In line with these observations, and with the growing evidence for the participation of ALK in the origin and progression of different types of tumors, 28 our findings support Human glioma or pancreatic cancer cell lines were cultured in DMEM containing 10% FBS. The preparation of adherent primary culture of brain tumor cells was as follows: tumor samples were homogenized, digested with type Ia collagenase (Sigma) for 90 min at 371C and incubated on ice for 10 min. The supernatant was collected and, after centrifugation to discard the remaining death-floating cells, resuspended in DMEM containing 15% FBS. Finally, cells were seeded at a density of 400 000 cells per cm 2 and kept in culture for 2 weeks in DMEM containing 15% FBS and 1% glutamine. Cells were transferred to a serum-free medium (human glioma cell lines), 0.5% FBS medium (primary cultures of glioma cells) or conditioned medium 18 h before performing the different treatments. When indicated, cells were preincubated with exogenous Mdk for 2 h or with NVP-TAE-684, SR1 or SR2 for 1 h before treatment with THC. Cell viability was determined after 72 h of THC treatment by using the MTT test (Promega, Madison, WI, USA) according to manufacturer's instructions. THC stock solution was prepared in dimethylsulfoxide. Control incubations contained the same amount of dimethylsulfoxide and no significant effect was observed in any of the parameters determined throughout this study at the final concentration used (0.1-0.2%, v/v).
Analysis of gene expression by cDNA microarrays. Total RNA was isolated from human glioma cells lines with RNeasy Mini Kit (Qiagen, Hilden, Germany). Double-stranded cDNA was amplified with Superscript Choice System and T7-(deoxythymidine)24 oligo-primers (Life Technologies, Inc., Gaithersburg, MD, USA) and in vitro transcription was carried out with Megascript T7 (Ambion, Austin, TX, USA). Samples were labeled with Cy3-dUTP (Amersham, Uppsala, Sweden) and Universal Human Reference RNA (Stratagene, La Jolla, CA, USA) with Cy5-dUTP (Amersham) and hybridized on an advanced version of the Spanish National Cancer Research Centre (CNIO) Oncochip (http://bioinfo.cnio.es/data/oncochip) as described in the MIAME. Slides were scanned in a Scanarray 5000 XL scanner (GSI Lumonics Kanata, Ontario, Canada) and the data matrices were processed with GenePix 6.0 software (Axon, Instruments Inc., Union City, CA, USA).
Human Mdk ELISA bioassay. Soluble Mdk levels were determined by using the Human Midkine ELISA (Biovendor, Heidelberg, Germany).
Conditioned medium experiments. U87 or T98 cells were seeded in complete medium at a density of 30 000 cells per cm 2 and, after 8 h, transferred to a serum-free medium for 18 h. Media were subsequently recovered, centrifuged and incubated alone or with an anti-Mdk antibody (20 mg/ml; Ref: sc-20715, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or with an isotype antibody (rabbit IgG; 20 mg/ml; Amersham Biosciences Corp., Piscataway, NJ, USA) for 1 h at 371C. To study the influence of the conditioned media (obtained as described above) on cell viability, U87 cells were seeded in complete medium at a density of 5000 cells per cm 2 and, after 8 h, transferred to the corresponding conditioned medium 18 h before performing the different treatments. Finally, cell viability was determined as described above.
Transfections. T98, LN405, HG2, or Panc1 (75% confluent) cells were transfected with control (siC), human Mdk (siMdk) or human ALK (siALK) siRNAs using the X-tremeGENE siRNA Transfection Reagent (Roche, Basel, Switzerland) according to manufacturer's instructions. After 24 h of transfection, cells were trypsinized and seeded in complete medium at a density of 5000 cells per cm 2 . After 8 h, cells were transferred to a serum-free (cell lines) or 0.5% FBS (primary culture) medium for 18 h and the different treatments were performed. Transfection efficiency was monitored using a control fluorescent siRNA (Qiagen). The efficacy of transfection was higher than 80% in all the experiments.
Reverse transcriptionand real-time quantitive-PCR analysis. RNA was isolated using the RNeasy Protect kit (Qiagen) including a DNase digestion step using the RNase-free DNase kit (Qiagen). cDNA was subsequently obtained using Transcriptor Reverse Transcriptase (Roche). PCR reactions were performed using the following parameters: 951C for 5 min, 941C for 30 s, 581C for 30 s, and 721C for 1 min followed by a final extension step of 721C for 5 min. The number of cycles (23-25 cycles for human Mdk and 22-25 cycles for GAPDH) was adjusted to allow detection in the linear range. Finally, PCR products were separated on 1.5% agarose gels. Real-time quantitive PCR assays were performed using the FastStart Master Mix with Rox (Roche) and probes were obtained from the Universal Probe Library Set (Roche). Amplifications were run in a 7900 HT-Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). Each value was adjusted using 18S RNA levels as reference. Primers sequences and probes used in this study can be found in Supplementary Table 8 .
Tumor xenografts. Tumors were induced by subcutaneous injection in nude mice of 10 Â 10 6 U87 or T98 cells in PBS supplemented with 0.1% glucose. When tumors had reached an average size of 250 mm 3 (an average of 2 weeks for U87 tumors and 14 weeks for T98 tumors), animals were assigned randomly to various groups and injected peritumorally for 15 days with the corresponding treatment (THC (15 mg/kg per day), NVP-TAE-684 (1 mg/kg per day) or THC (15 mg/kg per day) þ NVP-TAE-684 (1 mg/kg per day)) or vehicle in 100 ml of PBS supplemented with 5 mg/ml defatted and dialyzed BSA. Tumors were measured with external caliper, and volume was calculated as (4p/3) Â (width/2) 2 Â (length/2). At the end of the treatment, animals were killed, all tumors were excised and their weights were determined. 
